LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics

Lymphocyte activation gene 3 (LAG‐3) or CD223 is a transmembrane protein that serves as an immune checkpoint which attenuates T‐cell activation. Many clinical trials of LAG‐3 inhibitors have had modest effects, but recent data indicate that the LAG‐3 antibody relatlimab, together with nivolumab (anti‐PD‐1), provided greater benefit than nivolumab alone in patients with melanoma.

[1]  R. Kurzrock,et al.  Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials , 2022, ESMO open.

[2]  D. Schadendorf,et al.  Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. , 2022, The New England journal of medicine.

[3]  A. Godkin,et al.  Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity , 2021, Immunotherapy advances.

[4]  S. Lippman,et al.  Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden , 2021, Journal of Hematology & Oncology.

[5]  J. Sicklick,et al.  Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study , 2021, Genome medicine.

[6]  J. Wolchok,et al.  LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade , 2021, Science Translational Medicine.

[7]  L. Fashoyin-Aje,et al.  Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health , 2021, The oncologist.

[8]  E. Felip,et al.  Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma. , 2021 .

[9]  E. Ruppin,et al.  Synthetic lethality-mediated precision oncology via the tumor transcriptome , 2021, Cell.

[10]  R. Kurzrock,et al.  Missing the target in cancer therapy , 2021, Nature Cancer.

[11]  Y. Xin,et al.  Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy , 2021, Journal of Experimental & Clinical Cancer Research.

[12]  A. Haydon,et al.  Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma , 2020, Journal for ImmunoTherapy of Cancer.

[13]  T. Okazaki,et al.  LAG-3: from molecular functions to clinical applications , 2020, Journal for ImmunoTherapy of Cancer.

[14]  Charles J. Vaske,et al.  Transcriptomic silencing as a potential mechanism of treatment resistance. , 2020, JCI insight.

[15]  Felicia L. Lenzo,et al.  Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity , 2020, Oncoimmunology.

[16]  E. Ruppin,et al.  Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1. , 2019, JAMA oncology.

[17]  S. Piha-Paul,et al.  Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies. , 2019, Journal of Clinical Oncology.

[18]  J Jack Lee,et al.  Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial , 2019, Nature Medicine.

[19]  D. Vignali,et al.  Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. , 2019, Seminars in immunology.

[20]  David M. Thomas,et al.  Diagnosis of fusion genes using targeted RNA sequencing , 2019, Nature Communications.

[21]  E. Jaffee,et al.  PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. , 2019, JCI insight.

[22]  T. Okazaki,et al.  Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation , 2019, The Journal of Biological Chemistry.

[23]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[24]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[25]  Jinxiang Chen,et al.  The effect of immune microenvironment on the progression and prognosis of colorectal cancer , 2014, Medical Oncology.

[26]  D. Speiser,et al.  MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial , 2014, Journal of Translational Medicine.

[27]  Peter Vogel,et al.  Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .

[28]  Pedro Romero,et al.  Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. , 2011, The Journal of clinical investigation.

[29]  M. Gutiérrez,et al.  First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity , 2010, Journal of Translational Medicine.

[30]  B. Escudier,et al.  A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma , 2009, Clinical Cancer Research.

[31]  D. Vignali,et al.  Biochemical Analysis of the Regulatory T Cell Protein Lymphocyte Activation Gene-3 (LAG-3; CD223)1 , 2004, The Journal of Immunology.

[32]  Mark Gardner,et al.  Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. , 2018, The Journal of molecular diagnostics : JMD.

[33]  K. Kinzler,et al.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.